Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.

Michael J. Overman,Greg Yothers,Samuel A. Jacobs,Hanna K. Sanoff,Deirdre Jill Cohen,Katherine A. Guthrie,Norah Lynn Henry,Patricia A. Ganz,Scott Kopetz,Peter C. Lucas,Charles D. Blanke,Norman Wolmark,Howard S. Hochster,Thomas J. George,Caio Max Sao Pedro Rocha Lima

Journal of Clinical Oncology（2021）

引用 0|浏览2

暂无评分

摘要

TPS3618Background: The superiority of inhibition of programmed cell death-1 (PD-1) pathway in dMMR/MSI-H over chemotherapy with either anti-vascular endothelial growth factor receptor (VEGFr) or an...

查看译文

关键词

metastatic colorectal cancer,colorectal cancer,deficient dna mismatch repair,atezolizumab,microsatellite instability,immuno-therapy,first-line

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要